Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population.
In order to identify genetic polymorphisms and haplotype frequencies of CYP1A2 in a Japanese population, the enhancer and promoter regions, all the exons with their surrounding introns, and intron 1 were sequenced from genomic DNA from 250 Japanese subjects. Thirty-three polymorphisms were found, including 13 novel ones: 2 in the enhancer region, 5 in the exons, and 6 in the introns. The most common single nucleotide polymorphism (SNP) was -163C>A (CYP1A2*1F allele) with a 0.628 frequency. In addition to six previously reported non-synonymous SNPs, three novel ones, 125C>G (P42R, CYP1A2*15 allele, MPJ6_1A2032), 1130G>A (R377Q, *16 allele, MPJ6_1A2033), and 1367G>A (R456H, *8 allele, MPJ6_1A2019), were found with frequencies of 0.002, 0.002, and 0.004, respectively. No polymorphism was found in the known nuclear transcriptional factor-binding sites in the enhancer region. Based on linkage disequilibrium analysis, the CYP1A2 gene was analyzed as one haplotype block. Using the 33 detected polymorphisms, 14 haplotypes were unambiguously identified, and 17 haplotypes were inferred by aid of an expectation-maximization-based program. Among them, the second major haplotype CYP1A2*1L is composed of -3860G>A (*1C allele), -2467delT (*1D allele), and -163C>A (*1F allele). Network analysis suggested that relatively rare haplotypes were derived from three major haplotypes, *1A, *1M, and *1N in most cases. Our findings provide fundamental and useful information for genotyping CYP1A2 in the Japanese, and probably Asian populations.
Soyama
Akiko
A
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
Saito
Yoshiro
Y
Hanioka
Nobumitsu
N
Maekawa
Keiko
K
Komamura
Kazuo
K
Kamakura
Shiro
S
Kitakaze
Masafumi
M
Tomoike
Hitonobu
H
Ueno
Kazuyuki
K
Goto
Yu-ichi
Y
Kimura
Hideo
H
Katoh
Masaaki
M
Sugai
Kenji
K
Saitoh
Osamu
O
Kawai
Mitsuru
M
Ohnuma
Teiichi
T
Ohtsuki
Taisuke
T
Suzuki
Chieko
C
Minami
Narihiro
N
Kamatani
Naoyuki
N
Ozawa
Shogo
S
Sawada
Jun-ichi
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D001483:Base Sequence; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics*; D004247:DNA / Q000235:genetics; D017931:DNA Primers; D004742:Enhancer Elements, Genetic; D004827:Epilepsy / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D015894:Genome, Human; D006801:Humans; D007564:Japan; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000927:Anticonvulsants; D017931:DNA Primers; D004247:DNA; D019388:Cytochrome P-450 CYP1A2